miRNA-497 与肝细胞癌预后的 Meta 分析。

A Meta-Analysis of MiRNA-497 and Prognosis of Hepatocellular Carcinoma.

机构信息

Department of Epidemiology, The First Affiliated Hospital of Shandong First Medical University & Shandong Provincial Qianfoshan Hospital, No. 16766 Jingshi Road, Jinan 250014, Shandong, China.

Department of Peripheral Vascular, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan 250011, China.

出版信息

Can J Gastroenterol Hepatol. 2024 Mar 18;2024:2211179. doi: 10.1155/2024/2211179. eCollection 2024.

DOI:10.1155/2024/2211179

PMID:38529202

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10963114/

Abstract

BACKGROUND

Recently, microRNA-497 (miR-497) has been reported as a prognostic marker for hepatocellular carcinoma (HCC). However, there is no systematic study summarizing these data. Herein, we elucidated the prognostic role of miR497 in HCC by using meta-analysis.

METHODS

We systematically searched Embase, PubMed, Web of Science, and, China National Knowledge Infrastructure for relevant studies. The two researchers conducted data extraction and quality evaluation independently. We used hazard ratios (HRs), odds ratios (ORs), and their 95% confidence interval (95% CI) to evaluate the relationship between miR-497 expression level and HCC prognosis.

RESULTS

A total of 6 studies involving 457 participants were included in this meta-analysis. There was a significant association between the lower level of miR-497 expression and the shorter overall survival (HR = 2.17, 95% CI: 1.67-2.84, < 0.001). Meanwhile, patients with low miR-497 expression were more prone to vascular infiltration (OR = 2.73, 95%: 1.79-4.17, < 0.001). However, the lower expression level of miR-497 had no significant correlation with TNM (tumor-node-metastasis) stage (OR = 1.47, 95% CI: 0.17-12.49, =0.47).

CONCLUSIONS

MiR-497 might serve as a prognostic biomarker in HCC, but more clinical studies are needed to confirm this view.

摘要

背景

最近，miR-497（miR-497）被报道为肝细胞癌（HCC）的预后标志物。然而，尚无系统研究总结这些数据。在此，我们通过荟萃分析阐明了 miR497 在 HCC 中的预后作用。

方法

我们系统地检索了 Embase、PubMed、Web of Science 和中国知网，以获取相关研究。两位研究人员独立进行数据提取和质量评估。我们使用风险比（HRs）、比值比（ORs）及其 95%置信区间（95%CI）来评估 miR-497 表达水平与 HCC 预后之间的关系。

结果

共有 6 项研究纳入了 457 名参与者，进行了荟萃分析。miR-497 表达水平较低与总生存期较短之间存在显著相关性（HR=2.17，95%CI：1.67-2.84， < 0.001）。同时，miR-497 表达水平较低的患者更容易发生血管浸润（OR=2.73，95%CI：1.79-4.17， < 0.001）。然而，miR-497 表达水平较低与 TNM（肿瘤-淋巴结-转移）分期无显著相关性（OR=1.47，95%CI：0.17-12.49，=0.47）。